SCHEMBL1363498

SCHEMBL1363498

Nc1c(F)c(=O)[nH]c(=O)n1[C@@H]1O[C@@H]2COP(=O)(O)O[C@H]2[C@H]1O

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 11/20 0.52
PDE4A P27815 6/20 0.52
PDE4B Q07343 6/20 0.52
PDE4C Q08493 6/20 0.52
PDE4D Q08499 6/20 0.52
PDE3B Q13370 1/20 0.52
PDE3A Q14432 1/20 0.52
UMPS P11172 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364020 0.87 UMPS (0.48) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL3221107 0.85 STING1 (0.46) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL3219336 0.85 UMPS (0.52) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL15189724 0.82 UMPS (0.54) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL1362756 0.80 PDE4A (0.55) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL1363178 0.79 PDE4A (0.48) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL8537224 0.78 STING1 (0.56) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL3218084 0.78 DHFR (0.58) STING1
SCHEMBL1364784 0.75 PDE4A (0.50) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL1363426 0.75 PDE4A (0.50) STING1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931691-B1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA UNIV HEALTH NETWORK (CA) 2013-08-21 EP claimed
US-8067391-B2 ODCase inhibitors for the treatment of malaria UNIVERSITY HEALTH NETWORK (CA) 2011-11-29 US claimed
US-20100056468-A1 Pyrimidine Derivatives As Anticancer Agents UNIVERSITY HEALTH NETWORK (CA) 2010-03-04 US claimed
US-20090221524-A1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA UNIVERSITY HEALTH NETWORK (CA) 2009-09-03 US claimed
WO-2008083465-A1 PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS UNIVERSITY HEALTH NETWORK (CA) 2008-07-17 WO claimed
EP-1931691-A1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA University Health Network (CA) 2008-06-18 EP claimed
WO-2007038859-A1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA UNIVERSITY HEALTH NETWORK (CA) 2007-04-12 WO claimed
EP-1931691-B1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA UNIV HEALTH NETWORK (CA) 2013-08-21 EP disclosed
US-8067391-B2 ODCase inhibitors for the treatment of malaria UNIVERSITY HEALTH NETWORK (CA) 2011-11-29 US disclosed
US-20100056468-A1 Pyrimidine Derivatives As Anticancer Agents UNIVERSITY HEALTH NETWORK (CA) 2010-03-04 US disclosed
US-20090221524-A1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA UNIVERSITY HEALTH NETWORK (CA) 2009-09-03 US disclosed
WO-2008083465-A1 PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS UNIVERSITY HEALTH NETWORK (CA) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221524-A1 ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA UMPS, UGDH, UPP1 STING1 1416/4885PDE4A 327/4885PDE4B 321/4885
US-20100056468-A1 Pyrimidine Derivatives As Anticancer Agents DPYD, TYMP, TYMS STING1 598/4885PDE4A 2919/4885PDE4B 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.